APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-oncology Biopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Non-oncology Biopharmaceuticals Market Analysis and Forecast 2026-2032

20 December 2025211 pages

Choose your research edition.

Industry ResearchNon-oncology Biopharmaceuticals Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-oncology Biopharmaceuticals Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Non-oncology Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-oncology Biopharmaceuticals Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-oncology Biopharmaceuticals Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Non-oncology Biopharmaceuticals market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Non-oncology Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Non-oncology Biopharmaceuticals include Takeda, Teva, Sanofi, Johnson & Johnson, Novartis, Novo Nordisk, Merck, Mylan and Roche, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Non-oncology Biopharmaceuticals, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Non-oncology Biopharmaceuticals, also provides the revenue of main regions and countries. Of the upcoming market potential for Non-oncology Biopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Non-oncology Biopharmaceuticals revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Non-oncology Biopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Non-oncology Biopharmaceuticals revenue, projected growth trends, production technology, application and end-user industry.

Non-oncology Biopharmaceuticals Segment by Company

Takeda

Teva

Sanofi

Johnson & Johnson

Novartis

Novo Nordisk

Merck

Mylan

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Biogen

Amgen

AbbVie

AstraZeneca

UCB Pharma

Swedish Orphan Biovitrum

LEO Pharma

Elusys Therapeutics

Bristol-Myers Squibb

Boehringer Ingelheim

Alexion Pharmaceuticals

Non-oncology Biopharmaceuticals Segment by Type

Biologics

Biosimilars

Non-oncology Biopharmaceuticals Segment by Application

Immunology

Endocrinology

Others

Non-oncology Biopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-oncology Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-oncology Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-oncology Biopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Non-oncology Biopharmaceuticals in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Non-oncology Biopharmaceuticals company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-oncology Biopharmaceuticals revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Biologics Major Player Table 3. Biosimilars Major Player Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Immunology Major Player Table 6. Endocrinology Major Player Table 7. Others Major Player Table 8. Non-oncology Biopharmaceuticals Industry Trends Table 9. Non-oncology Biopharmaceuticals Industry Drivers Table 10. Non-oncology Biopharmaceuticals Industry Opportunities and Challenges Table 11. Non-oncology Biopharmaceuticals Industry Restraints Table 12. Global Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Non-oncology Biopharmaceuticals Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Non-oncology Biopharmaceuticals Market Share by Region (2021-2026) Table 15. Global Non-oncology Biopharmaceuticals Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Non-oncology Biopharmaceuticals Market Share by Region (2027-2032) Table 17. Global Non-oncology Biopharmaceuticals Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2021-2026) Table 19. Global Non-oncology Biopharmaceuticals Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Non-oncology Biopharmaceuticals Key Players Headquarters & Area Served Table 21. Global Non-oncology Biopharmaceuticals Players, Product Type & Application Table 22. Global Non-oncology Biopharmaceuticals Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Non-oncology Biopharmaceuticals by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Non-oncology Biopharmaceuticals Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Non-oncology Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2021-2026) Table 29. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2027-2032) Table 30. Global Non-oncology Biopharmaceuticals Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Non-oncology Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2021-2026) Table 34. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2027-2032) Table 35. Takeda Company Information Table 36. Takeda Business Overview Table 37. Takeda Non-oncology Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Takeda Non-oncology Biopharmaceuticals Product Portfolio Table 39. Takeda Recent Development Table 40. Teva Company Information Table 41. Teva Business Overview Table 42. Teva Non-oncology Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Teva Non-oncology Biopharmaceuticals Product Portfolio Table 44. Teva Recent Development Table 45. Sanofi Company Information Table 46. Sanofi Business Overview Table 47. Sanofi Non-oncology Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Sanofi Non-oncology Biopharmaceuticals Product Portfolio Table 49. Sanofi Recent Development Table 50. Johnson & Johnson Company Information Table 51. Johnson & Johnson Business Overview Table 52. Johnson & Johnson Non-oncology Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Johnson & Johnson Non-oncology Biopharmaceuticals Product Portfolio Table 54. Johnson & Johnson Recent Development Table 55. Novartis Company Information Table 56. Novartis Business Overview Table 57. Novartis Non-oncology Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Novartis Non-oncology Biopharmaceuticals Product Portfolio Table 59. Novartis Recent Development Table 60. Novo Nordisk Company Information Table 61. Novo Nordisk Business Overview Table 62. Novo Nordisk Non-oncology Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Novo Nordisk Non-oncology Biopharmaceuticals Product Portfolio Table 64. Novo Nordisk Recent Development Table 65. Merck Company Information Table 66. Merck Business Overview Table 67. Merck Non-oncology Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Merck Non-oncology Biopharmaceuticals Product Portfolio Table 69. Merck Recent Development Table 70. Mylan Company Information Table 71. Mylan Business Overview Table 72. Mylan Non-oncology Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Mylan Non-oncology Biopharmaceuticals Product Portfolio Table 74. Mylan Recent Development Table 75. Roche Company Information Table 76. Roche Business Overview Table 77. Roche Non-oncology Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Roche Non-oncology Biopharmaceuticals Product Portfolio Table 79. Roche Recent Development Table 80. Eli Lilly Company Information Table 81. Eli Lilly Business Overview Table 82. Eli Lilly Non-oncology Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Eli Lilly Non-oncology Biopharmaceuticals Product Portfolio Table 84. Eli Lilly Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Pfizer Non-oncology Biopharmaceuticals Product Portfolio Table 89. Pfizer Recent Development Table 90. GlaxoSmithKline Company Information Table 91. GlaxoSmithKline Business Overview Table 92. GlaxoSmithKline Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. GlaxoSmithKline Non-oncology Biopharmaceuticals Product Portfolio Table 94. GlaxoSmithKline Recent Development Table 95. Biogen Company Information Table 96. Biogen Business Overview Table 97. Biogen Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Biogen Non-oncology Biopharmaceuticals Product Portfolio Table 99. Biogen Recent Development Table 100. Amgen Company Information Table 101. Amgen Business Overview Table 102. Amgen Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Amgen Non-oncology Biopharmaceuticals Product Portfolio Table 104. Amgen Recent Development Table 105. AbbVie Company Information Table 106. AbbVie Business Overview Table 107. AbbVie Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. AbbVie Non-oncology Biopharmaceuticals Product Portfolio Table 109. AbbVie Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. AstraZeneca Non-oncology Biopharmaceuticals Product Portfolio Table 114. AstraZeneca Recent Development Table 115. UCB Pharma Company Information Table 116. UCB Pharma Business Overview Table 117. UCB Pharma Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. UCB Pharma Non-oncology Biopharmaceuticals Product Portfolio Table 119. UCB Pharma Recent Development Table 120. Swedish Orphan Biovitrum Company Information Table 121. Swedish Orphan Biovitrum Business Overview Table 122. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Portfolio Table 124. Swedish Orphan Biovitrum Recent Development Table 125. LEO Pharma Company Information Table 126. LEO Pharma Business Overview Table 127. LEO Pharma Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. LEO Pharma Non-oncology Biopharmaceuticals Product Portfolio Table 129. LEO Pharma Recent Development Table 130. Elusys Therapeutics Company Information Table 131. Elusys Therapeutics Business Overview Table 132. Elusys Therapeutics Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Elusys Therapeutics Non-oncology Biopharmaceuticals Product Portfolio Table 134. Elusys Therapeutics Recent Development Table 135. Bristol-Myers Squibb Company Information Table 136. Bristol-Myers Squibb Business Overview Table 137. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 138. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Portfolio Table 139. Bristol-Myers Squibb Recent Development Table 140. Boehringer Ingelheim Company Information Table 141. Boehringer Ingelheim Business Overview Table 142. Boehringer Ingelheim Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 143. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Portfolio Table 144. Boehringer Ingelheim Recent Development Table 145. Alexion Pharmaceuticals Company Information Table 146. Alexion Pharmaceuticals Business Overview Table 147. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 148. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Portfolio Table 149. Alexion Pharmaceuticals Recent Development Table 150. North America Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 151. North America Non-oncology Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 152. North America Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 153. North America Non-oncology Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 154. North America Non-oncology Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 155. North America Non-oncology Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 156. North America Non-oncology Biopharmaceuticals Revenue by Country (US$ Million) & (2027-2032) Table 157. Europe Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 158. Europe Non-oncology Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 159. Europe Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 160. Europe Non-oncology Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 161. Europe Non-oncology Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Europe Non-oncology Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 163. Europe Non-oncology Biopharmaceuticals Revenue by Country (US$ Million) & (2027-2032) Table 164. China Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 165. China Non-oncology Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 166. China Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 167. China Non-oncology Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 168. Asia Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 169. Asia Non-oncology Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 170. Asia Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 171. Asia Non-oncology Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 172. Asia Non-oncology Biopharmaceuticals Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 173. Asia Non-oncology Biopharmaceuticals Revenue by Region (US$ Million) & (2021-2026) Table 174. Asia Non-oncology Biopharmaceuticals Revenue by Region (US$ Million) & (2027-2032) Table 175. SAMEA Non-oncology Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 176. SAMEA Non-oncology Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 177. SAMEA Non-oncology Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 178. SAMEA Non-oncology Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 179. SAMEA Non-oncology Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 180. SAMEA Non-oncology Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 181. SAMEA Non-oncology Biopharmaceuticals Revenue by Country (US$ Million) & (2027-2032) Table 182. Research Programs/Design for This Report Table 183. Authors List of This Report Table 184. Secondary Sources Table 185. Primary Sources List of Figures Figure 1. Non-oncology Biopharmaceuticals Image Figure 2. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-oncology Biopharmaceuticals Market Size Share 2021 VS 2025 VS 2032 Figure 4. Biologics Image Figure 5. Biosimilars Image Figure 6. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Non-oncology Biopharmaceuticals Market Size Share 2021 VS 2025 VS 2032 Figure 8. Immunology Image Figure 9. Endocrinology Image Figure 10. Others Image Figure 11. Global Non-oncology Biopharmaceuticals Market Size (US$ Million) & (2021-2032) Figure 12. Global Non-oncology Biopharmaceuticals Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Non-oncology Biopharmaceuticals Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Non-oncology Biopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Non-oncology Biopharmaceuticals Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2021-2032) Figure 19. Global Non-oncology Biopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2021-2032) Figure 22. North America Non-oncology Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Non-oncology Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 24. North America Non-oncology Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 25. North America Non-oncology Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 26. United States Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Non-oncology Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Non-oncology Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 31. Europe Non-oncology Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 32. Europe Non-oncology Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 33. Germany Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Non-oncology Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Non-oncology Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 43. China Non-oncology Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 44. Asia Non-oncology Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Non-oncology Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 46. Asia Non-oncology Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 47. Asia Non-oncology Biopharmaceuticals Revenue Share by Region (2021-2032) Figure 48. Japan Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Non-oncology Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Non-oncology Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 56. SAMEA Non-oncology Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 57. SAMEA Non-oncology Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 58. Brazil Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Non-oncology Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Biosimilars
Applications
  • Immunology
  • Endocrinology
  • Others
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Novo Nordisk
  • Merck
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Amgen
  • AbbVie
  • AstraZeneca
  • UCB Pharma
  • Swedish Orphan Biovitrum
  • LEO Pharma
  • Elusys Therapeutics
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Alexion Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Non-oncology Biopharmaceuticals Market by Type
  3. 1.2.1 Global Non-oncology Biopharmaceuticals Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Biologics
  5. 1.2.3 Biosimilars
  6. 1.3 Non-oncology Biopharmaceuticals Market by Application
  7. 1.3.1 Global Non-oncology Biopharmaceuticals Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Immunology
  9. 1.3.3 Endocrinology
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Non-oncology Biopharmaceuticals Market Dynamics
  1. 2.1 Non-oncology Biopharmaceuticals Industry Trends
  2. 2.2 Non-oncology Biopharmaceuticals Industry Drivers
  3. 2.3 Non-oncology Biopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 Non-oncology Biopharmaceuticals Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Non-oncology Biopharmaceuticals Market Perspective (2021-2032)
  2. 3.2 Global Non-oncology Biopharmaceuticals Growth Trends by Region
  3. 3.2.1 Global Non-oncology Biopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Non-oncology Biopharmaceuticals Market Size by Region (2021-2026)
  5. 3.2.3 Global Non-oncology Biopharmaceuticals Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Non-oncology Biopharmaceuticals Revenue by Players
  2. 4.1.1 Global Non-oncology Biopharmaceuticals Revenue by Players (2021-2026)
  3. 4.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Non-oncology Biopharmaceuticals Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Non-oncology Biopharmaceuticals Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Non-oncology Biopharmaceuticals Key Players Headquarters & Area Served
  7. 4.4 Global Non-oncology Biopharmaceuticals Players, Product Type & Application
  8. 4.5 Global Non-oncology Biopharmaceuticals Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Non-oncology Biopharmaceuticals Market CR5 and HHI
  11. 4.6.3 2025 Non-oncology Biopharmaceuticals Tier 1, Tier 2, and Tier 3
5 Non-oncology Biopharmaceuticals Market Size by Type
  1. 5.1 Global Non-oncology Biopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Non-oncology Biopharmaceuticals Revenue by Type (2021-2032)
  3. 5.3 Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2021-2032)
6 Non-oncology Biopharmaceuticals Market Size by Application
  1. 6.1 Global Non-oncology Biopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Non-oncology Biopharmaceuticals Revenue by Application (2021-2032)
  3. 6.3 Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Non-oncology Biopharmaceuticals Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Non-oncology Biopharmaceuticals Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Non-oncology Biopharmaceuticals Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Johnson & Johnson
  20. 7.4.1 Johnson & Johnson Company Information
  21. 7.4.2 Johnson & Johnson Business Overview
  22. 7.4.3 Johnson & Johnson Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Johnson & Johnson Non-oncology Biopharmaceuticals Product Portfolio
  24. 7.4.5 Johnson & Johnson Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Non-oncology Biopharmaceuticals Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 Novo Nordisk
  32. 7.6.1 Novo Nordisk Company Information
  33. 7.6.2 Novo Nordisk Business Overview
  34. 7.6.3 Novo Nordisk Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novo Nordisk Non-oncology Biopharmaceuticals Product Portfolio
  36. 7.6.5 Novo Nordisk Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck Non-oncology Biopharmaceuticals Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 Mylan
  44. 7.8.1 Mylan Company Information
  45. 7.8.2 Mylan Business Overview
  46. 7.8.3 Mylan Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Mylan Non-oncology Biopharmaceuticals Product Portfolio
  48. 7.8.5 Mylan Recent Developments
  49. 7.9 Roche
  50. 7.9.1 Roche Company Information
  51. 7.9.2 Roche Business Overview
  52. 7.9.3 Roche Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Roche Non-oncology Biopharmaceuticals Product Portfolio
  54. 7.9.5 Roche Recent Developments
  55. 7.10 Eli Lilly
  56. 7.10.1 Eli Lilly Company Information
  57. 7.10.2 Eli Lilly Business Overview
  58. 7.10.3 Eli Lilly Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Eli Lilly Non-oncology Biopharmaceuticals Product Portfolio
  60. 7.10.5 Eli Lilly Recent Developments
  61. 7.11 Pfizer
  62. 7.11.1 Pfizer Company Information
  63. 7.11.2 Pfizer Business Overview
  64. 7.11.3 Pfizer Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer Non-oncology Biopharmaceuticals Product Portfolio
  66. 7.11.5 Pfizer Recent Developments
  67. 7.12 GlaxoSmithKline
  68. 7.12.1 GlaxoSmithKline Company Information
  69. 7.12.2 GlaxoSmithKline Business Overview
  70. 7.12.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  71. 7.12.4 GlaxoSmithKline Non-oncology Biopharmaceuticals Product Portfolio
  72. 7.12.5 GlaxoSmithKline Recent Developments
  73. 7.13 Biogen
  74. 7.13.1 Biogen Company Information
  75. 7.13.2 Biogen Business Overview
  76. 7.13.3 Biogen Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Biogen Non-oncology Biopharmaceuticals Product Portfolio
  78. 7.13.5 Biogen Recent Developments
  79. 7.14 Amgen
  80. 7.14.1 Amgen Company Information
  81. 7.14.2 Amgen Business Overview
  82. 7.14.3 Amgen Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Amgen Non-oncology Biopharmaceuticals Product Portfolio
  84. 7.14.5 Amgen Recent Developments
  85. 7.15 AbbVie
  86. 7.15.1 AbbVie Company Information
  87. 7.15.2 AbbVie Business Overview
  88. 7.15.3 AbbVie Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  89. 7.15.4 AbbVie Non-oncology Biopharmaceuticals Product Portfolio
  90. 7.15.5 AbbVie Recent Developments
  91. 7.16 AstraZeneca
  92. 7.16.1 AstraZeneca Company Information
  93. 7.16.2 AstraZeneca Business Overview
  94. 7.16.3 AstraZeneca Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  95. 7.16.4 AstraZeneca Non-oncology Biopharmaceuticals Product Portfolio
  96. 7.16.5 AstraZeneca Recent Developments
  97. 7.17 UCB Pharma
  98. 7.17.1 UCB Pharma Company Information
  99. 7.17.2 UCB Pharma Business Overview
  100. 7.17.3 UCB Pharma Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  101. 7.17.4 UCB Pharma Non-oncology Biopharmaceuticals Product Portfolio
  102. 7.17.5 UCB Pharma Recent Developments
  103. 7.18 Swedish Orphan Biovitrum
  104. 7.18.1 Swedish Orphan Biovitrum Company Information
  105. 7.18.2 Swedish Orphan Biovitrum Business Overview
  106. 7.18.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Portfolio
  108. 7.18.5 Swedish Orphan Biovitrum Recent Developments
  109. 7.19 LEO Pharma
  110. 7.19.1 LEO Pharma Company Information
  111. 7.19.2 LEO Pharma Business Overview
  112. 7.19.3 LEO Pharma Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  113. 7.19.4 LEO Pharma Non-oncology Biopharmaceuticals Product Portfolio
  114. 7.19.5 LEO Pharma Recent Developments
  115. 7.20 Elusys Therapeutics
  116. 7.20.1 Elusys Therapeutics Company Information
  117. 7.20.2 Elusys Therapeutics Business Overview
  118. 7.20.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Elusys Therapeutics Non-oncology Biopharmaceuticals Product Portfolio
  120. 7.20.5 Elusys Therapeutics Recent Developments
  121. 7.21 Bristol-Myers Squibb
  122. 7.21.1 Bristol-Myers Squibb Company Information
  123. 7.21.2 Bristol-Myers Squibb Business Overview
  124. 7.21.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Portfolio
  126. 7.21.5 Bristol-Myers Squibb Recent Developments
  127. 7.22 Boehringer Ingelheim
  128. 7.22.1 Boehringer Ingelheim Company Information
  129. 7.22.2 Boehringer Ingelheim Business Overview
  130. 7.22.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Portfolio
  132. 7.22.5 Boehringer Ingelheim Recent Developments
  133. 7.23 Alexion Pharmaceuticals
  134. 7.23.1 Alexion Pharmaceuticals Company Information
  135. 7.23.2 Alexion Pharmaceuticals Business Overview
  136. 7.23.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Portfolio
  138. 7.23.5 Alexion Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Non-oncology Biopharmaceuticals Revenue (2021-2032)
  2. 8.2 North America Non-oncology Biopharmaceuticals Revenue by Type (2021-2032)
  3. 8.2.1 North America Non-oncology Biopharmaceuticals Revenue by Type (2021-2026)
  4. 8.2.2 North America Non-oncology Biopharmaceuticals Revenue by Type (2027-2032)
  5. 8.3 North America Non-oncology Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 8.4 North America Non-oncology Biopharmaceuticals Revenue by Application (2021-2032)
  7. 8.4.1 North America Non-oncology Biopharmaceuticals Revenue by Application (2021-2026)
  8. 8.4.2 North America Non-oncology Biopharmaceuticals Revenue by Application (2027-2032)
  9. 8.5 North America Non-oncology Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 8.6 North America Non-oncology Biopharmaceuticals Revenue by Country
  11. 8.6.1 North America Non-oncology Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Non-oncology Biopharmaceuticals Revenue by Country (2021-2026)
  13. 8.6.3 North America Non-oncology Biopharmaceuticals Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Non-oncology Biopharmaceuticals Revenue (2021-2032)
  2. 9.2 Europe Non-oncology Biopharmaceuticals Revenue by Type (2021-2032)
  3. 9.2.1 Europe Non-oncology Biopharmaceuticals Revenue by Type (2021-2026)
  4. 9.2.2 Europe Non-oncology Biopharmaceuticals Revenue by Type (2027-2032)
  5. 9.3 Europe Non-oncology Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 9.4 Europe Non-oncology Biopharmaceuticals Revenue by Application (2021-2032)
  7. 9.4.1 Europe Non-oncology Biopharmaceuticals Revenue by Application (2021-2026)
  8. 9.4.2 Europe Non-oncology Biopharmaceuticals Revenue by Application (2027-2032)
  9. 9.5 Europe Non-oncology Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 9.6 Europe Non-oncology Biopharmaceuticals Revenue by Country
  11. 9.6.1 Europe Non-oncology Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Non-oncology Biopharmaceuticals Revenue by Country (2021-2026)
  13. 9.6.3 Europe Non-oncology Biopharmaceuticals Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Non-oncology Biopharmaceuticals Revenue (2021-2032)
  2. 10.2 China Non-oncology Biopharmaceuticals Revenue by Type (2021-2032)
  3. 10.2.1 China Non-oncology Biopharmaceuticals Revenue by Type (2021-2026)
  4. 10.2.2 China Non-oncology Biopharmaceuticals Revenue by Type (2027-2032)
  5. 10.3 China Non-oncology Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 10.4 China Non-oncology Biopharmaceuticals Revenue by Application (2021-2032)
  7. 10.4.1 China Non-oncology Biopharmaceuticals Revenue by Application (2021-2026)
  8. 10.4.2 China Non-oncology Biopharmaceuticals Revenue by Application (2027-2032)
  9. 10.5 China Non-oncology Biopharmaceuticals Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Non-oncology Biopharmaceuticals Revenue (2021-2032)
  2. 11.2 Asia Non-oncology Biopharmaceuticals Revenue by Type (2021-2032)
  3. 11.2.1 Asia Non-oncology Biopharmaceuticals Revenue by Type (2021-2026)
  4. 11.2.2 Asia Non-oncology Biopharmaceuticals Revenue by Type (2027-2032)
  5. 11.3 Asia Non-oncology Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 11.4 Asia Non-oncology Biopharmaceuticals Revenue by Application (2021-2032)
  7. 11.4.1 Asia Non-oncology Biopharmaceuticals Revenue by Application (2021-2026)
  8. 11.4.2 Asia Non-oncology Biopharmaceuticals Revenue by Application (2027-2032)
  9. 11.5 Asia Non-oncology Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 11.6 Asia Non-oncology Biopharmaceuticals Revenue by Country
  11. 11.6.1 Asia Non-oncology Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Non-oncology Biopharmaceuticals Revenue by Country (2021-2026)
  13. 11.6.3 Asia Non-oncology Biopharmaceuticals Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Non-oncology Biopharmaceuticals Revenue (2021-2032)
  2. 12.2 SAMEA Non-oncology Biopharmaceuticals Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Non-oncology Biopharmaceuticals Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Non-oncology Biopharmaceuticals Revenue by Type (2027-2032)
  5. 12.3 SAMEA Non-oncology Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Non-oncology Biopharmaceuticals Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Non-oncology Biopharmaceuticals Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Non-oncology Biopharmaceuticals Revenue by Application (2027-2032)
  9. 12.5 SAMEA Non-oncology Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Non-oncology Biopharmaceuticals Revenue by Country
  11. 12.6.1 SAMEA Non-oncology Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Non-oncology Biopharmaceuticals Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Non-oncology Biopharmaceuticals Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst